ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NVRO Nevro Corp

11.17
0.61 (5.78%)
After Hours
Last Updated: 21:31:38
Delayed by 15 minutes
Share Name Share Symbol Market Type
Nevro Corp NYSE:NVRO NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.61 5.78% 11.17 11.18 10.35 10.43 528,952 21:31:38

Nevro to Report Operating Results for the First Quarter 2017

24/04/2017 9:10pm

PR Newswire (US)


Nevro (NYSE:NVRO)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Nevro Charts.

REDWOOD CITY, Calif., April 24, 2017 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it will release financial results for the first quarter of 2017 after market close on Monday, May 8, 2017. Company management will host a conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Monday, May 8, 2017.

Investors interested in listening to the conference call may do so by dialing (877) 201-0168 for U.S. callers, or (647) 788-4901 for international callers (Conference ID: 6073641), or from the webcast on the "Investors" section of the Company's website at www.nevro.com/investors. Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website.

About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Investor Relations Contact:
Nevro Investor Relations
Katherine Bock
(650) 433-3247
ir@nevro.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nevro-to-report-operating-results-for-the-first-quarter-2017-300444316.html

SOURCE Nevro Corp.

Copyright 2017 PR Newswire

1 Year Nevro Chart

1 Year Nevro Chart

1 Month Nevro Chart

1 Month Nevro Chart

Your Recent History

Delayed Upgrade Clock